Nrx pharmaceuticals announces initiation of phase 2b trial of brilife™ vaccine for covid-19 in nation of georgia

Radnor, pa., aug. 9, 2021 /prnewswire/ -- nrx pharmaceuticals (nrx) (nasdaq: nrxp), a clinical stage, global biopharmaceutical company today announced it is initiating a phase 2b dose-confirmatory trial of the brilife™ vaccine against covid-19 in the nation of georgia.
NRXP Ratings Summary
NRXP Quant Ranking